吉非替尼靶向治疗非小细胞肺癌的临床疗效及对患者预后的影响

Clinical efficacy of gefitinib targeted therapy for non-small cell lung cancer and its impact on patient prognosis

目的探讨吉非替尼靶向治疗非小细胞肺癌(NSCLC)的临床疗效及对患者预后的影响。方法依据治疗方案的不同将102例NSCLC患者分为对照组(n=50)和观察组(n=52),对照组患者给予多西他赛+顺铂化疗,观察组患者给予吉非替尼联合多西他赛+顺铂化疗。比较两组患者的临床疗效、血清肿瘤标志物[糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)]水平、不良反应发生情况和预后情况。结果观察组患者的总缓解率为61.54%,明显高于对照组患者的32.00%(P﹤0.01)。治疗后,两组患者CA125、NSE、CEA水平均低于本组治疗前(P﹤0.05),且观察组患者CA125、NSE、CEA水平均低于对照组(P﹤0.05)。观察组患者的不良反应总发生率为19.23%,低于对照组患者的40.00%(P﹤0.05)。治疗2周、6个月,观察组患者格拉斯哥昏迷评分均明显高于对照组(P﹤0.01)。结论吉非替尼靶向治疗可明显提高NSCLC患者的临床疗效,改善血清肿瘤标志物水平和预后,且不良反应轻微。

Objective To investigate the clinical efficacy of gefitinib targeted therapy for non-small cell lung cancer(NSCLC)and its impact on the prognosis of patients.Method According to different treatment regimens,102 patients of NSCLC were divided into control group(n=50)and observation group(n=52).The control group were given docetaxel+cisplatin chemotherapy,and the observation group were given gefitinib combined with docetaxel+cisplatin chemotherapy.The clinical efficacy,serum tumor markers[carbohydrate antigen 125(CA125),neuron specific enolase(NSE),carcinoembryonic antigen(CEA)]levels,adverse reactions and prognosis were compared between the two groups.Result The total remission rate in the observation group was 61.54%,which was significantly higher than 32.00% in the control group(P<0.01).After treatment,the levels of CA125,NSE and CEA in the two groups were lower than those before treatment(P<0.05),and the levels of CA125,NSE and CEA in the observation group were lower than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was 19.23%,which was lower than 40.00% in the control group(P<0.05).After 2 weeks and 6 months of treatment,the Glasgow coma scores in the observation group were significantly higher than that in the control group(P<0.01).Conclusion Gefitinib targeted therapy can significantly improve the clinical efficacy of NSCLC patients,improve serum tumor marker levels and prognosis,with mild adverse reactions.